Carregant...
No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19
BACKGROUND: The use of hydroxychloroquine (HCQ), with or without concurrent administration of azithromycin (AZM), for treatment of COVID-19 has received considerable attention. The purpose of this study was to determine whether HCQ administration is associated with improved mortality in COVID-19 pat...
Guardat en:
| Publicat a: | Int J Infect Dis |
|---|---|
| Autors principals: | , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7834474/ https://ncbi.nlm.nih.gov/pubmed/33359949 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijid.2020.12.060 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|